This content is from: United States Vaccines and Vidal: what pharma in-house are watching in 2022 Innovator and generics counsel weigh in on key court cases and why they have high hopes for Kathi Vidal By Rani Mehta January 14 2022
This content is from: Mexico Mexico transforms patent processes by adapting online solutions By Mauricio Sámano January 17 2022
This content is from: International Exclusive: IP5 joint meeting with TM5/ID5 scrapped By Rory O’Neill January 14 2022
This content is from: Singapore This week in IP: Vidal and Stark nominations progress, Singapore passes major IP bill, ... By Max Walters & Patrick Wingrove & Rani Mehta & Sukanya Sarkar January 14 2022
This content is from: International The ‘loneliness’ of starting your own IP firm By Rory O’Neill January 13 2022
This content is from: European Union Opinion: France’s six-month IP plan is welcome but too ambitious By Max Walters January 13 2022
This content is from: United States Opinion: SCOTUS study is good idea, but little will come of it By Rani Mehta January 12 2022
This content is from: United States Patent splurging: how in-house would spend budget increases Four lawyers tell Managing IP that they would invest in people, foreign filings and patent quality if their budgets went up by 20% or more By Rani Mehta January 07 2022
